查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790288

美國伴侶動物骨關節炎市場規模、佔有率和趨勢分析報告：按產品、動物、給藥途徑、最終用途和細分市場預測，2025 年至 2033 年

U.S. Companion Animal Osteoarthritis Market Size, Share & Trends Analysis Report By Product (Biologics, Pharmaceuticals, Viscosupplements, Nutritional Supplements), By Animal, By Route of Administration, By End-use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國伴侶動物骨關節炎市場摘要

美國伴侶動物骨關節炎市場規模預計在 2024 年為 7.7697 億美元，預計到 2033 年將達到 41.974 億美元，2025 年至 2033 年的複合年成長率為 22.55%。預計推動市場發展的關鍵因素包括骨關節炎盛行率上升、研發舉措增加、新治療方法出現以及宣傳宣傳活動增加。

在科技創新的推動下，美國伴侶動物骨關節炎（CA OA）市場正經歷強勁成長。

提高臨床意識，擴大多樣化治療方案的可近性。先進的治療方法

預防性照護措施與飼主主導的結合正在重塑寵物（尤其是犬類）骨關節炎的治療方式。其中最有前景的進展之一是基因療法的進步。

ElenaVet 等基因療法的進展已證明，在減輕骨關節炎犬疼痛和改善其活動能力方面，成功率高達 90%。這項治療方法凸顯了向緩解疾病療法的轉變，與傳統的疼痛管理療法相比，這些療法具有長期益處。

同時，正如《DVM360》所報導的那樣，由獸醫主導的宣傳活動透過強調早期發現、活動篩檢和積極的骨關節炎管理，正在提高護理標準。這種臨床關注度的提高，使飼主，並能夠及時開始治療，從而擴大了整體市場。

與這些努力相輔相成的是，專門針對犬骨關節炎（OA）配製的營養補充品日益增加。最近在美國推出的一款新型補充劑 (DVM360) 為早期和輔助治療管理提供了處方箋選擇，特別適合注重成本或尋求整體解決方案的飼主飼主。

同時，幹細胞療法等再生療法在專科診所和尖端診所中日益受到青睞。正如 Fitzpatrick Referrals 所述，這些治療方法是微創解決方案，專注於關節修復而非症狀抑制，這與人們對長期修復治療日益成長的期望相吻合。

進一步增強市場競爭力的是目前正在臨床開發中的口服治療藥物，包括Can-Fite和Vetbiolix的Piclidenoson。這款A3Adenosine受體促效劑旨在提供一種便捷、非侵入性的治療方案，預計2034年全球銷售額將達到峰值，超過4.45億美元。該藥物的進展反映了投資者和臨床醫生對口服骨關節炎治療作為注射藥物和非類固醇消炎劑的可行替代方案的強烈信心。

總而言之，美國伴侶動物骨關節炎市場正受到全面而多方面的變革驅動，從尖端的基因和細胞療法，到不斷提升的從業人員教育和動物主人參與度。這個多元化的生態系統正在改善患者的治療效果，並鞏固美國在伴侶動物骨關節炎治療的全球領導地位。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國伴侶動物骨關節炎市場趨勢與展望

  • 市場體系展望
    • 母市場
    • 子公司市場
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 伴侶動物骨關節炎市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 主要國家的法規結構
    • 主要動物物種數量預估（2021-2024）
    • 管道/臨床試驗分析
    • COVID-19影響分析

第4章美國伴侶動物骨關節炎市場：按產品的估計和趨勢分析

  • 細分儀表板
  • 美國伴侶動物骨關節炎市場：產品差異分析
  • 2021 年至 2033 年美國伴侶動物骨關節炎市場規模及趨勢分析（依產品）
  • 生物製藥
    • 幹細胞
    • 富血小板血漿（PRP）
    • 單株抗體（mAb）
    • 其他生物製藥
  • 黏稠補充劑
  • 製藥
    • 類固醇
    • NSAIDs
    • 其他
  • 營養補充品

第5章美國伴侶動物骨關節炎市場：按物種的估計和趨勢分析

  • 細分儀表板
  • 美國伴侶動物骨關節炎市場：動物變異分析
  • 美國伴侶動物骨關節炎市場規模與趨勢分析（按動物，2021-2033 年）
  • 狗
  • 貓
  • 馬

第6章美國伴侶動物骨關節炎市場：按給藥途徑的估計和趨勢分析

  • 細分儀表板
  • 美國伴侶動物骨關節炎市場：按給藥途徑進行的變化分析
  • 美國伴侶動物骨關節炎市場規模及趨勢分析（依給藥途徑），2021-2033 年
    • 口服
    • 注射
    • 肌肉注射
    • 關節內
    • 其他注射藥物
    • 其他

第7章美國伴侶動物骨關節炎市場：按最終用途的估計和趨勢分析

  • 細分儀表板
  • 美國伴侶動物骨關節炎市場：依最終用途的變化分析
  • 美國伴侶動物骨關節炎市場規模及趨勢分析（依最終用途），2021-2033 年
    • 獸醫院/診所
    • 電子商務
    • 其他

第8章 競爭態勢

  • 市場參與企業分類
  • 企業市場分析/堆圖分析
  • 公司簡介
    • Zoetis Inc.
    • Boehringer Ingelheim
    • Elanco Animal Health
    • American Regent, Inc.
    • Merck Animal Health（Merck &Co. Inc）
    • Vetoquinol SA
    • Ceva Sante Animale
    • Virbac
    • Biogenesis Bago
    • Ardent Animal Health, LLC
    • PetVivo Holdings, Inc.（Spryng）
    • Vet Stem Inc.
    • Enso Discoveries
    • Contura Vet US
    • T-Cyte Therapeutics
    • Medrego LLC.
  • 戰略地圖
  • 主要企業名單
Product Code: GVR-4-68040-669-7

U.S. Companion Animal Osteoarthritis Market Summary

The U.S. companion animal osteoarthritis market size was estimated at USD 776.97 million in 2024 and is projected to reach USD 4,197.40 million by 2033, growing at a CAGR of 22.55% from 2025 to 2033. Key factors expected to drive the market include the rising prevalence of osteoarthritis, increasing R&D initiative, emerging novel treatments, and increasing awareness campaigns.

The U.S. companion animal osteoarthritis (CA OA) market is undergoing robust growth, fueled by innovation,

increased clinical awareness, and broader access to diverse treatment options. A convergence of advanced therapies,

preventive care initiatives, and owner-driven demand is reshaping how OA is managed in pets, particularly dogs. One of the most promising developments is the advancement of gene therapy, exemplified by CureLab Veterinary's

ElenaVet, which demonstrated a remarkable 90% success rate in reducing pain and improving mobility in dogs with OA. This breakthrough highlights a shift toward disease-modifying approaches that offer longer-term benefits compared to conventional pain management therapies.

At the same time, veterinary-led awareness campaigns-as reported by DVM360-are raising the standard of care by emphasizing early detection, mobility screening, and proactive OA management. This growing clinical emphasis has led to better-informed pet owners and more timely treatment initiation, expanding the overall addressable market.

Complementing these efforts is the increasing availability of nutritional supplements specifically formulated for canine OA. The recent U.S. launch of a new supplement (DVM360) provides a non-prescription option for managing early-stage or adjunctive care, especially for cost-conscious pet owners or those seeking holistic solutions.

In parallel, regenerative therapies, such as stem cell treatments, are gaining momentum in specialty practices and progressive clinics. As outlined by Fitzpatrick Referrals, these therapies offer minimally invasive solutions that focus on joint restoration rather than symptom suppression-aligning with rising expectations for long-lasting, restorative care.

Further strengthening the market is a growing pipeline of oral therapeutics, including Can-Fite and Vetbiolix's Piclidenoson, currently in advanced clinical development. This A3 adenosine receptor agonist is positioned to offer a convenient, non-invasive treatment option with global peak sales projected to exceed $445 million by 2034. Its progress reflects strong investor and clinical confidence in oral OA therapies as viable alternatives to injectables and NSAIDs.

In conclusion, the U.S. CA OA market is being driven by a comprehensive, multi-modal evolution-from cutting-edge gene and cell therapies to increased practitioner education and owner engagement. This diversified ecosystem improves patient outcomes and solidifies the U.S. as a global front-runner in advancing osteoarthritis care for companion animals.

U.S. Companion Animal Osteoarthritis Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. companion animal osteoarthritis market report based on product, animal, route of administration, and end use:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Biologics
    • Stem Cells
    • Platelet-Rich Plasma (PRP)
    • Monoclonal Antibodies (mAb)
    • Other Biologics
  • Viscosupplements
  • Pharmaceuticals
    • Steroids
    • NSAIDS
    • Others
  • Nutritional Supplements
  • Animal Outlook (Revenue, USD Million, 2021 - 2033)
  • Canine
  • Equine
  • Feline
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Injectable
    • Intra-muscular
    • Intra-articular
    • Other Injectable
  • Topical
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Veterinary Hospitals/Clinics
  • E-commerce
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Country Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Companion Animal Osteoarthritis Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Prevalence of Osteoarthitis
      • 3.2.1.2. Increasing R&D Initiatives
      • 3.2.1.3. Emerging Novel Treatments
      • 3.2.1.4. Increasing Awareness Campaigns
      • 3.2.1.5. Advancing Diagnostic Techniques Increasing Adoption of OA Treatment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory Hurdles
      • 3.2.2.2. Emerging Adverse Drug Reactions (ADR)
      • 3.2.2.3. Stringent Regulations
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Companion Animal Osteoarthritis Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework by Key Countries
    • 3.3.4. Estimated Animal Population, by Key Species, 2021 - 2024
    • 3.3.5. Pipeline/ Clinical Trials Analysis
    • 3.3.6. COVID-19 Impact Analysis

Chapter 4. U.S. Companion Animal Osteoarthritis Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Companion Animal Osteoarthritis Market: Product Movement Analysis
  • 4.3. U.S. Companion Animal Osteoarthritis Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
  • 4.4. Biologics
    • 4.4.1. Biologics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Stem Cells
      • 4.4.2.1. Stem Cells Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Platelet-Rich Plasma (PRP)
      • 4.4.3.1. Platelet-Rich Plasma (PRP) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Monoclonal Antibodies (mAb)
      • 4.4.4.1. Monoclonal Antibodies (mAb) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Other Biologics
      • 4.4.5.1. Other Biologics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Viscosupplements
    • 4.5.1. Viscosupplements Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Pharmaceuticals
    • 4.6.1. Pharmaceuticals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Steroids
      • 4.6.2.1. Steroids Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. NSAIDs
      • 4.6.3.1. NSAIDs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.4. Others
      • 4.6.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Nutritional Supplements
      • 4.7.1.1. Nutritional Supplements Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Companion Animal Osteoarthritis Market: Animal Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Companion Animal Osteoarthritis Market: Animal Movement Analysis
  • 5.3. U.S. Companion Animal Osteoarthritis Market Size & Trend Analysis, by animal, 2021 to 2033 (USD Million)
  • 5.4. Canine
    • 5.4.1. Canine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Feline
    • 5.5.1. Feline Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Equine
    • 5.6.1. Equine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Companion Animal Osteoarthritis Market: By Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Companion Animal Osteoarthritis Market: By Route of Administration Movement Analysis
  • 6.3. U.S. Companion Animal Osteoarthritis Market Size & Trend Analysis, by route of administration, 2021 to 2033 (USD Million)
    • 6.3.1. Oral
      • 6.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Injectables
      • 6.3.2.1. Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Intra-muscular
      • 6.3.3.1. Intra-muscular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.4. Intra-articular
      • 6.3.4.1. Intra-articular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.5. Other Injectables
      • 6.3.5.1. Other Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.6. Others
      • 6.3.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Companion Animal Osteoarthritis Market: By End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Companion Animal Osteoarthritis Market: By End Use Movement Analysis
  • 7.3. U.S. Companion Animal Osteoarthritis Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
    • 7.3.1. Veterinary Hospitals/Clinics
      • 7.3.1.1. Veterinary Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. E-commerce
      • 7.3.2.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Others
      • 7.3.3.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Position Analysis/ Heap Map Analysis
  • 8.3. Company Profiles
    • 8.3.1. Zoetis Inc.
      • 8.3.1.1. Participant's Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Boehringer Ingelheim
      • 8.3.2.1. Participant's Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Elanco Animal Health
      • 8.3.3.1. Participant's Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. American Regent, Inc.
      • 8.3.4.1. Participant's Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Merck Animal Health (Merck & Co. Inc)
      • 8.3.5.1. Participant's Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Vetoquinol S.A.
      • 8.3.6.1. Participant's Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Ceva Sante Animale
      • 8.3.7.1. Participant's Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Virbac
      • 8.3.8.1. Participant's Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Biogenesis Bago
      • 8.3.9.1. Participant's Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Ardent Animal Health, LLC
      • 8.3.10.1. Participant's Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. PetVivo Holdings, Inc. (Spryng)
      • 8.3.11.1. Participant's Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Vet Stem Inc.
      • 8.3.12.1. Participant's Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. Enso Discoveries
      • 8.3.13.1. Participant's Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Product Benchmarking
      • 8.3.13.4. Strategic Initiatives
    • 8.3.14. Contura Vet US
      • 8.3.14.1. Participant's Overview
      • 8.3.14.2. Financial Performance
      • 8.3.14.3. Product Benchmarking
      • 8.3.14.4. Strategic Initiatives
    • 8.3.15. T-Cyte Therapeutics
      • 8.3.15.1. Participant's Overview
      • 8.3.15.2. Financial Performance
      • 8.3.15.3. Product Benchmarking
      • 8.3.15.4. Strategic Initiatives
    • 8.3.16. Medrego LLC.
      • 8.3.16.1. Participant's Overview
      • 8.3.16.2. Financial Performance
      • 8.3.16.3. Product Benchmarking
      • 8.3.16.4. Strategic Initiatives
  • 8.4. Strategy Mapping
      • 8.4.1.1. Mergers & Acquisitions
      • 8.4.1.2. Partnerships & Collaborations
      • 8.4.1.3. Expansion
      • 8.4.1.4. Product launch
      • 8.4.1.5. Product Approval
      • 8.4.1.6. Others
  • 8.5. List of Key Companies
      • 8.5.1.1. List of Manufacturers
      • 8.5.1.2. List of Distributors

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Companion Animal Osteoarthritis Market, By Product, 2021 - 2033 (USD Million)
  • Table 4 U.S. Companion Animal Osteoarthritis Market, By Animal, 2021 - 2033 (USD Million)
  • Table 5 U.S. Companion Animal Osteoarthritis Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 6 U.S. Companion Animal Osteoarthritis Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 U.S. Companion Animal Osteoarthritis Market, Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 U.S. Companion Animal Osteoarthritis Market, for By Product, 2021 - 2033 (USD Million)
  • Fig. 14 U.S. Companion Animal Osteoarthritis Market, for Biologics, 2021 - 2033 (USD Million)
  • Fig. 15 U.S. Companion Animal Osteoarthritis Market, for Stem Cells, 2021 - 2033 (USD Million)
  • Fig. 16 U.S. Companion Animal Osteoarthritis Market, for Platelet-Rich Plasma (PRP), 2021 - 2033 (USD Million)
  • Fig. 17 U.S. Companion Animal Osteoarthritis Market, for Monoclonal Antibodies (mAb), 2021 - 2033 (USD Million)
  • Fig. 18 U.S. Companion Animal Osteoarthritis Market, for Other Biologics, 2021 - 2033 (USD Million)
  • Fig. 19 U.S. Companion Animal Osteoarthritis Market, for Viscosupplements, 2021 - 2033 (USD Million)
  • Fig. 20 U.S. Companion Animal Osteoarthritis Market, for Pharmaceuticals, 2021 - 2033 (USD Million)
  • Fig. 21 U.S. Companion Animal Osteoarthritis Market, for Steroids, 2021 - 2033 (USD Million)
  • Fig. 22 U.S. Companion Animal Osteoarthritis Market, for NSAIDS, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. Companion Animal Osteoarthritis Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 24 U.S. Companion Animal Osteoarthritis Market, for Nutritional Supplements, 2021 - 2033 (USD Million)
  • Fig. 25 U.S. Companion Animal Osteoarthritis Market, for By Animal, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. Companion Animal Osteoarthritis Market, for Canine, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. Companion Animal Osteoarthritis Market, for Equine, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. Companion Animal Osteoarthritis Market, for Feline, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. Companion Animal Osteoarthritis Market, for By Route of Administration, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Companion Animal Osteoarthritis Market, for Oral, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. Companion Animal Osteoarthritis Market, for Injectable, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. Companion Animal Osteoarthritis Market, for Intra-muscular, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. Companion Animal Osteoarthritis Market, for Intra-articular, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. Companion Animal Osteoarthritis Market, for Other Injectable, 2021 - 2033 (USD Million)
  • Fig. 35 U.S. Companion Animal Osteoarthritis Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 36 U.S. Companion Animal Osteoarthritis Market, for By End Use, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. Companion Animal Osteoarthritis Market, for Veterinary Hospitals/Clinics, 2021 - 2033 (USD Million)
  • Fig. 38 U.S. Companion Animal Osteoarthritis Market, for E-commerce, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. Companion Animal Osteoarthritis Market, for Others, 2021 - 2033 (USD Million)